The Absolute Effect / Evidence index
Neoadjuvant / Perioperative · Phase II multicentre randomized open-label; N=125 resectable stage III–IVB HNSCC. Neoadjuvant camrelizumab+nab-paclitaxel+carboplatin, surgery, risk-adapted adjuvant therapy and camrelizumab maintenance vs surgery-based standard care. Primary endpoint 2-year EFS. · 2-year EFS 77.8% vs 46.1%
CAMORAL
Clinical question: Does perioperative camrelizumab plus chemotherapy improve 2-year EFS over surgery-based standard care in resectable locally advanced HNSCC?
2-year EFS 77.8% vs 46.1%; HR 0.34 (95% CI 0.17–0.68; P=0.001); absolute gain 31.7 points; NNT 4. · Registry:
Design, population and treatment
Phase II multicentre randomized open-label; N=125 resectable stage III–IVB HNSCC. Neoadjuvant camrelizumab+nab-paclitaxel+carboplatin, surgery, risk-adapted adjuvant therapy and camrelizumab maintenance vs surgery-based standard care. Primary endpoint 2-year EFS.
Key efficacy outcome
Grade ≥3 treatment-emergent AEs 79.4% vs 56.5%; one fatal TEAE in control; surgery rates similar.
Safety and absolute effect
2-year EFS (%)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2856378
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.